Hippocratic AI is positioned as a key healthcare-focused participant in the broader surge of AI agent investment in 2025, a year marked by growing confidence that agentic systems can move beyond conversational use cases into real-world action. The company, which develops AI agents for healthcare applications, raised a $126 million Series C, reflecting strong investor interest in applying agent-based AI to clinical and patient-facing workflows amid rising competition across the sector.
The article also highlights major venture firms backing Hippocratic AI as part of their broader AI agent strategies. Andreessen Horowitz, headquartered in Menlo Park, has been among the most active investors in the category, completing 31 AI agent deals with a median deal size of $19.40 million and including Hippocratic AI alongside companies such as EliseAI and Decagon in its portfolio. General Catalyst, based in San Francisco, has made 24 deals with a higher median deal size of $73.52 million and has backed Hippocratic AI in addition to agentic startups like Windsurf and General Intuition, underscoring sustained, high-conviction investment in AI agents across multiple industries, including healthcare.